Abstract
The existence of stable, transcriptionally silent human immunodeficiency virus (HIV) in latently infected cells represents a major obstacle to acquired immune deficiency syndrome (AIDS) therapy. Histone deacetylase (HDAC) can inhibit histone acetylation, resulting in HIV-1 provirus transcription silence. Apicidin, a widely used antiparasitic drug, exhibits antiparasitic activity by inhibiting HDAC. Using the latently infected A10.6 cell line, we describe the dose- and time-dependent manner in which Apicidin reverses HIV-1 latency. We found that Apicidin can synergize with trichostatin A (TSA) to activate HIV-1 gene expression. Chromatin immunoprecipitation (ChIP) assay further indicates that Apicidin induces HIV-1 reactivation by increasing the acetylation levels of H3 and H4 at nucleosome 1 in HIV-1 long terminal repeats (LTR). Our research reveals a potent activator for reactivating latent HIV-1 and shows promise for HIV-1 therapy.
Keywords: AIDS, apicidin, human immunodeficiency virus type 1, histone acetylation, histone deacetylase inhibitors, latent reservoirs, Cytotoxicity, Cell Culture, Cytometry Analysis, Toxicity Assay
Current HIV Research
Title: HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells
Volume: 9 Issue: 4
Author(s): Shiguan Lin, Yuhao Zhang, Hao Ying and Huanzhang Zhu
Affiliation:
Keywords: AIDS, apicidin, human immunodeficiency virus type 1, histone acetylation, histone deacetylase inhibitors, latent reservoirs, Cytotoxicity, Cell Culture, Cytometry Analysis, Toxicity Assay
Abstract: The existence of stable, transcriptionally silent human immunodeficiency virus (HIV) in latently infected cells represents a major obstacle to acquired immune deficiency syndrome (AIDS) therapy. Histone deacetylase (HDAC) can inhibit histone acetylation, resulting in HIV-1 provirus transcription silence. Apicidin, a widely used antiparasitic drug, exhibits antiparasitic activity by inhibiting HDAC. Using the latently infected A10.6 cell line, we describe the dose- and time-dependent manner in which Apicidin reverses HIV-1 latency. We found that Apicidin can synergize with trichostatin A (TSA) to activate HIV-1 gene expression. Chromatin immunoprecipitation (ChIP) assay further indicates that Apicidin induces HIV-1 reactivation by increasing the acetylation levels of H3 and H4 at nucleosome 1 in HIV-1 long terminal repeats (LTR). Our research reveals a potent activator for reactivating latent HIV-1 and shows promise for HIV-1 therapy.
Export Options
About this article
Cite this article as:
Lin Shiguan, Zhang Yuhao, Ying Hao and Zhu Huanzhang, HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells, Current HIV Research 2011; 9 (4) . https://dx.doi.org/10.2174/157016211796320333
DOI https://dx.doi.org/10.2174/157016211796320333 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Reviews on Recent Clinical Trials Exome Sequencing of Ovarian Cancer Patients to Identify Variants Predictive of Sensitivity to Platinum-based Chemotherapy
Current Pharmacogenomics and Personalized Medicine Patent Selections
Recent Patents on Regenerative Medicine Light-at-Night-Induced Circadian Disruption, Cancer and Aging
Current Aging Science Lynch Syndrome: Awareness among Medical Students at a United States Medical School
Current Women`s Health Reviews Subject Index to Volume 9
Current Pharmaceutical Design Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment
Current Pharmaceutical Biotechnology Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Patent Selections:
Current Biomarkers (Discontinued) New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Current Medicinal Chemistry Treatment of Estrogen Receptor-Positive Breast Cancer
Current Medicinal Chemistry Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry The Use of Microarrays to Study Childhood Developmental Brain Disorders
Current Genomics Pharmacophore Searching of Benzofuran Derivatives for Selective CYP19 Aromatase Inhibition
Letters in Drug Design & Discovery Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Structure and Function of the Human Nuclear Xenobiotic Receptor PXR
Current Drug Metabolism